| Assay ID | Title | Year | Journal | Article |
|---|
| AID1347090 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347092 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347108 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347104 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1296008 | Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening | 2020 | SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
| Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening. |
| AID1347100 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347102 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347106 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for control Hh wild type fibroblast cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347091 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1508630 | Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay | 2021 | Cell reports, 04-27, Volume: 35, Issue:4
| A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome. |
| AID1347099 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347105 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1346986 | P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen | 2019 | Molecular pharmacology, 11, Volume: 96, Issue:5
| A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. |
| AID1347097 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347095 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347082 | qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal | 2020 | Antiviral research, 01, Volume: 173 | A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity. |
| AID1347093 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347086 | qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal | 2020 | Antiviral research, 01, Volume: 173 | A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity. |
| AID1347094 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347101 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1745845 | Primary qHTS for Inhibitors of ATXN expression | | | |
| AID1347154 | Primary screen GU AMC qHTS for Zika virus inhibitors | 2020 | Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
| Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors. |
| AID1347089 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347107 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh30 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347083 | qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen | 2020 | Antiviral research, 01, Volume: 173 | A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity. |
| AID1347098 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347096 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for U-2 OS cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347103 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1346987 | P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen | 2019 | Molecular pharmacology, 11, Volume: 96, Issue:5
| A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. |
| AID700649 | Inhibition of LRRK2 in C57BL/6 mouse spleen at 3 mg/kg, ip by ADP-acylphosphate probe-based mass spectrometry relative to vehicle-treated control | 2012 | ACS medicinal chemistry letters, Aug-09, Volume: 3, Issue:8
| Brain Penetrant LRRK2 Inhibitor. |
| AID702045 | Half life in mouse at 1 mg/kg, iv | 2012 | Journal of medicinal chemistry, Jun-14, Volume: 55, Issue:11
| Discovery of selective LRRK2 inhibitors guided by computational analysis and molecular modeling. |
| AID700631 | Inhibition of LRRK2 G2019S mutant autophosphorylation at Ser910 and Ser935 Parkinson's patient EBV immortalized primary lymphoblastoid cells after 90 mins by immunoblotting analysis | 2012 | ACS medicinal chemistry letters, Aug-09, Volume: 3, Issue:8
| Brain Penetrant LRRK2 Inhibitor. |
| AID700654 | Inhibition of JNK3 in ip dosed C57BL/6 mouse brain by ADP-acylphosphate probe-based mass spectrometry | 2012 | ACS medicinal chemistry letters, Aug-09, Volume: 3, Issue:8
| Brain Penetrant LRRK2 Inhibitor. |
| AID700644 | Inhibition of LRRK2 autophosphorylation at Ser910 and Ser935 in C57BL/6 mouse brain at 30 mg/kg, ip by immunoblotting analysis relative to vehicle-treated control | 2012 | ACS medicinal chemistry letters, Aug-09, Volume: 3, Issue:8
| Brain Penetrant LRRK2 Inhibitor. |
| AID700638 | Inhibition of LRRK2 autophosphorylation at Ser910 and Ser935 in C57BL/6 mouse brain at 100 mg/kg, ip by immunoblotting analysis relative to vehicle-treated control | 2012 | ACS medicinal chemistry letters, Aug-09, Volume: 3, Issue:8
| Brain Penetrant LRRK2 Inhibitor. |
| AID707016 | Time dependent inhibition of CYP1A2 | 2012 | Journal of medicinal chemistry, Nov-26, Volume: 55, Issue:22
| Discovery of highly potent, selective, and brain-penetrable leucine-rich repeat kinase 2 (LRRK2) small molecule inhibitors. |
| AID707018 | Apparent permeability from apical to basolateral side of MDCK cells expressing human MDR1 | 2012 | Journal of medicinal chemistry, Nov-26, Volume: 55, Issue:22
| Discovery of highly potent, selective, and brain-penetrable leucine-rich repeat kinase 2 (LRRK2) small molecule inhibitors. |
| AID700642 | Inhibition of LRRK2 autophosphorylation at Ser910 and Ser935 in C57BL/6 mouse kidney at 50 mg/kg, ip by immunoblotting analysis relative to vehicle-treated control | 2012 | ACS medicinal chemistry letters, Aug-09, Volume: 3, Issue:8
| Brain Penetrant LRRK2 Inhibitor. |
| AID700628 | Inhibition of LRRK2 A2016T mutant autophosphorylation at Ser910 and Ser935 expressed in HEK293 cells at 1 to 3 uM after 90 mins by immunoblotting analysis | 2012 | ACS medicinal chemistry letters, Aug-09, Volume: 3, Issue:8
| Brain Penetrant LRRK2 Inhibitor. |
| AID700661 | Inhibition of MNK2 at 10 uM by radiometric assay | 2012 | ACS medicinal chemistry letters, Aug-09, Volume: 3, Issue:8
| Brain Penetrant LRRK2 Inhibitor. |
| AID700624 | Inhibition of LRRK2 autophosphorylation at Ser910 and Ser935 expressed in HEK293 cells after 90 mins by immunoblotting analysis | 2012 | ACS medicinal chemistry letters, Aug-09, Volume: 3, Issue:8
| Brain Penetrant LRRK2 Inhibitor. |
| AID702040 | Inhibition of LRRK2 G2019S mutant at 1 uM | 2012 | Journal of medicinal chemistry, Jun-14, Volume: 55, Issue:11
| Discovery of selective LRRK2 inhibitors guided by computational analysis and molecular modeling. |
| AID700650 | Inhibition of LRRK2 in C57BL/6 mouse spleen at 10 mg/kg, ip by ADP-acylphosphate probe-based mass spectrometry relative to vehicle-treated control | 2012 | ACS medicinal chemistry letters, Aug-09, Volume: 3, Issue:8
| Brain Penetrant LRRK2 Inhibitor. |
| AID700652 | Inhibition of JNK1 in ip dosed C57BL/6 mouse brain by ADP-acylphosphate probe-based mass spectrometry | 2012 | ACS medicinal chemistry letters, Aug-09, Volume: 3, Issue:8
| Brain Penetrant LRRK2 Inhibitor. |
| AID700655 | Inhibition of TBK1 in ip dosed C57BL/6 mouse brain by ADP-acylphosphate probe-based mass spectrometry | 2012 | ACS medicinal chemistry letters, Aug-09, Volume: 3, Issue:8
| Brain Penetrant LRRK2 Inhibitor. |
| AID700640 | Inhibition of LRRK2 autophosphorylation at Ser910 and Ser935 in C57BL/6 mouse spleen at 100 mg/kg, ip by immunoblotting analysis relative to vehicle-treated control | 2012 | ACS medicinal chemistry letters, Aug-09, Volume: 3, Issue:8
| Brain Penetrant LRRK2 Inhibitor. |
| AID702039 | Inhibition of LRRK2 at 1 uM | 2012 | Journal of medicinal chemistry, Jun-14, Volume: 55, Issue:11
| Discovery of selective LRRK2 inhibitors guided by computational analysis and molecular modeling. |
| AID700626 | Inhibition of LRRK2 autophosphorylation at Ser910 and Ser935 expressed in HEK293 cells at 1 uM after 90 mins by immunoblotting analysis | 2012 | ACS medicinal chemistry letters, Aug-09, Volume: 3, Issue:8
| Brain Penetrant LRRK2 Inhibitor. |
| AID702044 | Ratio of fAUC in brain to plasma of P-gp/BCRp knock out mouse at 1 mg/kg, iv | 2012 | Journal of medicinal chemistry, Jun-14, Volume: 55, Issue:11
| Discovery of selective LRRK2 inhibitors guided by computational analysis and molecular modeling. |
| AID702041 | Ratio of AUC (total) in brain to plasma of wild type FVB mouse at 1 mg/kg, iv | 2012 | Journal of medicinal chemistry, Jun-14, Volume: 55, Issue:11
| Discovery of selective LRRK2 inhibitors guided by computational analysis and molecular modeling. |
| AID700990 | Inhibition of LRRK2 autophosphorylation at Ser910 and Ser935 in C57BL/6 mouse brain at 10 mg/kg, ip by immunoblotting analysis relative to vehicle-treated control | 2012 | ACS medicinal chemistry letters, Aug-09, Volume: 3, Issue:8
| Brain Penetrant LRRK2 Inhibitor. |
| AID702047 | Fraction unbound in wild type FVB mouse plasma at 30 mg/kg, ip after 1 hr | 2012 | Journal of medicinal chemistry, Jun-14, Volume: 55, Issue:11
| Discovery of selective LRRK2 inhibitors guided by computational analysis and molecular modeling. |
| AID700664 | Inhibition of LRRK2 G2019S mutant at 1 uM by radiometric assay | 2012 | ACS medicinal chemistry letters, Aug-09, Volume: 3, Issue:8
| Brain Penetrant LRRK2 Inhibitor. |
| AID700657 | Inhibition of JNK2 in C57BL/6 mouse brain at 50 and 100 mg/kg, ip by ADP-acylphosphate probe-based mass spectrometry relative to vehicle-treated control | 2012 | ACS medicinal chemistry letters, Aug-09, Volume: 3, Issue:8
| Brain Penetrant LRRK2 Inhibitor. |
| AID702046 | Total plasma concentration in wild type FVB mouse at 30 mg/kg, ip after 1 hr | 2012 | Journal of medicinal chemistry, Jun-14, Volume: 55, Issue:11
| Discovery of selective LRRK2 inhibitors guided by computational analysis and molecular modeling. |
| AID707022 | Inhibition of LRRK2 G2019S mutant at 1 uM | 2012 | Journal of medicinal chemistry, Nov-26, Volume: 55, Issue:22
| Discovery of highly potent, selective, and brain-penetrable leucine-rich repeat kinase 2 (LRRK2) small molecule inhibitors. |
| AID700622 | Inhibition of LRRK2 A2016T mutant expressed in HEK293 cells using nictide as substrate and [gamma32P]ATP after 15 mins by Cerenkov counting method | 2012 | ACS medicinal chemistry letters, Aug-09, Volume: 3, Issue:8
| Brain Penetrant LRRK2 Inhibitor. |
| AID700639 | Inhibition of LRRK2 autophosphorylation at Ser910 and Ser935 in C57BL/6 mouse kidney at 100 mg/kg, ip by immunoblotting analysis relative to vehicle-treated control | 2012 | ACS medicinal chemistry letters, Aug-09, Volume: 3, Issue:8
| Brain Penetrant LRRK2 Inhibitor. |
| AID700635 | Half life in mouse at 1 mg/kg, iv | 2012 | ACS medicinal chemistry letters, Aug-09, Volume: 3, Issue:8
| Brain Penetrant LRRK2 Inhibitor. |
| AID707024 | Inhibition of autophosphorylation of LRRK2 in human HEK293 cells | 2012 | Journal of medicinal chemistry, Nov-26, Volume: 55, Issue:22
| Discovery of highly potent, selective, and brain-penetrable leucine-rich repeat kinase 2 (LRRK2) small molecule inhibitors. |
| AID700658 | Inhibition of JNK3 in C57BL/6 mouse brain at 50 and 100 mg/kg, ip by ADP-acylphosphate probe-based mass spectrometry relative to vehicle-treated control | 2012 | ACS medicinal chemistry letters, Aug-09, Volume: 3, Issue:8
| Brain Penetrant LRRK2 Inhibitor. |
| AID700651 | Inhibition of LRRK2 in C57BL/6 mouse spleen at 30 to 100 mg/kg, ip by ADP-acylphosphate probe-based mass spectrometry relative to vehicle-treated control | 2012 | ACS medicinal chemistry letters, Aug-09, Volume: 3, Issue:8
| Brain Penetrant LRRK2 Inhibitor. |
| AID700637 | Half life in mouse liver microsomes at 1 uM | 2012 | ACS medicinal chemistry letters, Aug-09, Volume: 3, Issue:8
| Brain Penetrant LRRK2 Inhibitor. |
| AID707026 | Inhibition of LRRK2 using FAM-LRRKtide as substrate after 120 mins by microfluidic capillary electrophoresis assay | 2012 | Journal of medicinal chemistry, Nov-26, Volume: 55, Issue:22
| Discovery of highly potent, selective, and brain-penetrable leucine-rich repeat kinase 2 (LRRK2) small molecule inhibitors. |
| AID702049 | Free drug level in FVB mouse brain at 30 mg/kg, ip after 1 hr | 2012 | Journal of medicinal chemistry, Jun-14, Volume: 55, Issue:11
| Discovery of selective LRRK2 inhibitors guided by computational analysis and molecular modeling. |
| AID700625 | Inhibition of LRRK2 G2019S mutant autophosphorylation at Ser910 and Ser935 expressed in HEK293 cells after 90 mins by immunoblotting analysis | 2012 | ACS medicinal chemistry letters, Aug-09, Volume: 3, Issue:8
| Brain Penetrant LRRK2 Inhibitor. |
| AID702042 | Ratio of AUC (total) in brain to plasma of P-gp/BCRp knock out mouse at 1 mg/kg, iv | 2012 | Journal of medicinal chemistry, Jun-14, Volume: 55, Issue:11
| Discovery of selective LRRK2 inhibitors guided by computational analysis and molecular modeling. |
| AID707025 | Inhibition of wild type LRRK2 at 1 uM | 2012 | Journal of medicinal chemistry, Nov-26, Volume: 55, Issue:22
| Discovery of highly potent, selective, and brain-penetrable leucine-rich repeat kinase 2 (LRRK2) small molecule inhibitors. |
| AID702038 | Inhibition of Abl at 1 uM | 2012 | Journal of medicinal chemistry, Jun-14, Volume: 55, Issue:11
| Discovery of selective LRRK2 inhibitors guided by computational analysis and molecular modeling. |
| AID700653 | Inhibition of JNK2 in ip dosed C57BL/6 mouse brain by ADP-acylphosphate probe-based mass spectrometry | 2012 | ACS medicinal chemistry letters, Aug-09, Volume: 3, Issue:8
| Brain Penetrant LRRK2 Inhibitor. |
| AID700623 | Inhibition of LRRK2 G2019S/A2016T mutant expressed in HEK293 cells using nictide as substrate and [gamma32P]ATP after 15 mins by Cerenkov counting method | 2012 | ACS medicinal chemistry letters, Aug-09, Volume: 3, Issue:8
| Brain Penetrant LRRK2 Inhibitor. |
| AID700988 | Inhibition of LRRK2 in C57BL/6 mouse brain at 30 mg/kg, ip by ADP-acylphosphate probe-based mass spectrometry relative to vehicle-treated control | 2012 | ACS medicinal chemistry letters, Aug-09, Volume: 3, Issue:8
| Brain Penetrant LRRK2 Inhibitor. |
| AID700648 | Inhibition of LRRK2 in C57BL/6 mouse brain at 100 mg/kg, ip by ADP-acylphosphate probe-based mass spectrometry relative to vehicle-treated control | 2012 | ACS medicinal chemistry letters, Aug-09, Volume: 3, Issue:8
| Brain Penetrant LRRK2 Inhibitor. |
| AID700656 | Inhibition of JNK1 in C57BL/6 mouse brain at 50 and 100 mg/kg, ip by ADP-acylphosphate probe-based mass spectrometry relative to vehicle-treated control | 2012 | ACS medicinal chemistry letters, Aug-09, Volume: 3, Issue:8
| Brain Penetrant LRRK2 Inhibitor. |
| AID700636 | AUClast in mouse at 10 mg/kg, po | 2012 | ACS medicinal chemistry letters, Aug-09, Volume: 3, Issue:8
| Brain Penetrant LRRK2 Inhibitor. |
| AID700621 | Inhibition of LRRK2 G2019S mutant expressed in HEK293 cells using nictide as substrate and [gamma32P]ATP after 15 mins by Cerenkov counting method | 2012 | ACS medicinal chemistry letters, Aug-09, Volume: 3, Issue:8
| Brain Penetrant LRRK2 Inhibitor. |
| AID1450256 | Inhibition of LRRK2 G2019S mutant (unknown origin) using biotinylated ezrin/radaxin/meosin peptide as substrate measured after 1 hr | 2017 | Bioorganic & medicinal chemistry letters, 06-01, Volume: 27, Issue:11
| Discovery of LRRK2 inhibitors by using an ensemble of virtual screening methods. |
| AID707023 | Selectivity ratio of Ki for JAK2 to Ki for LRRK2 | 2012 | Journal of medicinal chemistry, Nov-26, Volume: 55, Issue:22
| Discovery of highly potent, selective, and brain-penetrable leucine-rich repeat kinase 2 (LRRK2) small molecule inhibitors. |
| AID700647 | Inhibition of LRRK2 in C57BL/6 mouse brain at 50 mg/kg, ip by ADP-acylphosphate probe-based mass spectrometry relative to vehicle-treated control | 2012 | ACS medicinal chemistry letters, Aug-09, Volume: 3, Issue:8
| Brain Penetrant LRRK2 Inhibitor. |
| AID700646 | Inhibition of LRRK2 in ip dosed C57BL/6 mouse spleen by ADP-acylphosphate probe-based mass spectrometry | 2012 | ACS medicinal chemistry letters, Aug-09, Volume: 3, Issue:8
| Brain Penetrant LRRK2 Inhibitor. |
| AID700645 | Inhibition of LRRK2 in ip dosed C57BL/6 mouse brain by ADP-acylphosphate probe-based mass spectrometry | 2012 | ACS medicinal chemistry letters, Aug-09, Volume: 3, Issue:8
| Brain Penetrant LRRK2 Inhibitor. |
| AID700620 | Inhibition of LRRK2 expressed in HEK293 cells using nictide as substrate and [gamma32P]ATP after 15 mins by Cerenkov counting method | 2012 | ACS medicinal chemistry letters, Aug-09, Volume: 3, Issue:8
| Brain Penetrant LRRK2 Inhibitor. |
| AID700634 | Oral bioavailability in mouse at 10 mg/kg | 2012 | ACS medicinal chemistry letters, Aug-09, Volume: 3, Issue:8
| Brain Penetrant LRRK2 Inhibitor. |
| AID702043 | Ratio of fAUC in brain to plasma of wild type FVB mouse at 1 mg/kg, iv | 2012 | Journal of medicinal chemistry, Jun-14, Volume: 55, Issue:11
| Discovery of selective LRRK2 inhibitors guided by computational analysis and molecular modeling. |
| AID702036 | Inhibition of JAK2 | 2012 | Journal of medicinal chemistry, Jun-14, Volume: 55, Issue:11
| Discovery of selective LRRK2 inhibitors guided by computational analysis and molecular modeling. |
| AID700630 | Inhibition of LRRK2 autophosphorylation at Ser910 and Ser935 human EBV immortalized primary lymphoblastoid cells after 90 mins by immunoblotting analysis | 2012 | ACS medicinal chemistry letters, Aug-09, Volume: 3, Issue:8
| Brain Penetrant LRRK2 Inhibitor. |
| AID1450255 | Inhibition of full length wild-type LRRK2 (unknown origin) using biotinylated ezrin/radaxin/meosin peptide as substrate measured after 1 hr | 2017 | Bioorganic & medicinal chemistry letters, 06-01, Volume: 27, Issue:11
| Discovery of LRRK2 inhibitors by using an ensemble of virtual screening methods. |
| AID702048 | Drug uptake in wild type FVB mouse brain at 30 mg/kg, ip after 1 hr | 2012 | Journal of medicinal chemistry, Jun-14, Volume: 55, Issue:11
| Discovery of selective LRRK2 inhibitors guided by computational analysis and molecular modeling. |
| AID707019 | Plasma protein binding in rat | 2012 | Journal of medicinal chemistry, Nov-26, Volume: 55, Issue:22
| Discovery of highly potent, selective, and brain-penetrable leucine-rich repeat kinase 2 (LRRK2) small molecule inhibitors. |
| AID700659 | Inhibition of TBK1 in C57BL/6 mouse brain at 50 and 100 mg/kg, ip by ADP-acylphosphate probe-based mass spectrometry relative to vehicle-treated control | 2012 | ACS medicinal chemistry letters, Aug-09, Volume: 3, Issue:8
| Brain Penetrant LRRK2 Inhibitor. |
| AID702037 | Selectivity index, ratio of Ki for JAK2 to Ki for LRRK2 | 2012 | Journal of medicinal chemistry, Jun-14, Volume: 55, Issue:11
| Discovery of selective LRRK2 inhibitors guided by computational analysis and molecular modeling. |
| AID700663 | Inhibition of MNK2 by radiometric assay | 2012 | ACS medicinal chemistry letters, Aug-09, Volume: 3, Issue:8
| Brain Penetrant LRRK2 Inhibitor. |
| AID700641 | Inhibition of LRRK2 autophosphorylation at Ser910 and Ser935 in C57BL/6 mouse brain at 50 mg/kg, ip by immunoblotting analysis relative to vehicle-treated control | 2012 | ACS medicinal chemistry letters, Aug-09, Volume: 3, Issue:8
| Brain Penetrant LRRK2 Inhibitor. |
| AID707017 | Efflux ratio of permeability from apical to basolateral over basolateral to apical side in MDCK cells expressing human MDR1 | 2012 | Journal of medicinal chemistry, Nov-26, Volume: 55, Issue:22
| Discovery of highly potent, selective, and brain-penetrable leucine-rich repeat kinase 2 (LRRK2) small molecule inhibitors. |
| AID700633 | Inhibition of LRRK2 autophosphorylation at Ser910 and Ser935 mouse embryonic fibroblast cells by immunoblotting analysis | 2012 | ACS medicinal chemistry letters, Aug-09, Volume: 3, Issue:8
| Brain Penetrant LRRK2 Inhibitor. |
| AID707021 | Clearance in human hepatocytes | 2012 | Journal of medicinal chemistry, Nov-26, Volume: 55, Issue:22
| Discovery of highly potent, selective, and brain-penetrable leucine-rich repeat kinase 2 (LRRK2) small molecule inhibitors. |
| AID702035 | Inhibition of LRRK2 | 2012 | Journal of medicinal chemistry, Jun-14, Volume: 55, Issue:11
| Discovery of selective LRRK2 inhibitors guided by computational analysis and molecular modeling. |
| AID700660 | Inhibition of MLK1 at 10 uM by radiometric assay | 2012 | ACS medicinal chemistry letters, Aug-09, Volume: 3, Issue:8
| Brain Penetrant LRRK2 Inhibitor. |
| AID707020 | Clearance in rat hepatocytes | 2012 | Journal of medicinal chemistry, Nov-26, Volume: 55, Issue:22
| Discovery of highly potent, selective, and brain-penetrable leucine-rich repeat kinase 2 (LRRK2) small molecule inhibitors. |
| AID700662 | Inhibition of MLK1 by radiometric assay | 2012 | ACS medicinal chemistry letters, Aug-09, Volume: 3, Issue:8
| Brain Penetrant LRRK2 Inhibitor. |
| AID700643 | Inhibition of LRRK2 autophosphorylation at Ser910 and Ser935 in C57BL/6 mouse spleen at 50 mg/kg, ip by immunoblotting analysis relative to vehicle-treated control | 2012 | ACS medicinal chemistry letters, Aug-09, Volume: 3, Issue:8
| Brain Penetrant LRRK2 Inhibitor. |
| AID700665 | Inhibition of cKIT L576P mutant at 1 uM by radiometric assay | 2012 | ACS medicinal chemistry letters, Aug-09, Volume: 3, Issue:8
| Brain Penetrant LRRK2 Inhibitor. |
| AID700632 | Inhibition of LRRK2 autophosphorylation at Ser910 and Ser935 Swiss mouse 3T3 cells by immunoblotting analysis | 2012 | ACS medicinal chemistry letters, Aug-09, Volume: 3, Issue:8
| Brain Penetrant LRRK2 Inhibitor. |
| AID700629 | Inhibition of LRRK2 G2019S/A2016T mutant autophosphorylation at Ser910 and Ser935 expressed in HEK293 cells at 1 to 3 uM after 90 mins by immunoblotting analysis | 2012 | ACS medicinal chemistry letters, Aug-09, Volume: 3, Issue:8
| Brain Penetrant LRRK2 Inhibitor. |
| AID700989 | Inhibition of LRRK2 G2019S mutant autophosphorylation at Ser910 and Ser935 expressed in HEK293 cells at 0.3 uM after 90 mins by immunoblotting analysis | 2012 | ACS medicinal chemistry letters, Aug-09, Volume: 3, Issue:8
| Brain Penetrant LRRK2 Inhibitor. |
| AID1347159 | Primary screen GU Rhodamine qHTS for Zika virus inhibitors: Unlinked NS2B-NS3 protease assay | 2020 | Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
| Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors. |
| AID1347411 | qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Mechanism Interrogation Plate v5.0 (MIPE) Libary | 2020 | ACS chemical biology, 07-17, Volume: 15, Issue:7
| High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle. |
| AID1347160 | Primary screen NINDS Rhodamine qHTS for Zika virus inhibitors | 2020 | Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
| Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors. |
| AID1345714 | Human Janus kinase 2 (Janus kinase (JakA) family) | 2012 | Journal of medicinal chemistry, Jun-14, Volume: 55, Issue:11
| Discovery of selective LRRK2 inhibitors guided by computational analysis and molecular modeling. |
| AID1345739 | Human leucine rich repeat kinase 2 (Leucine-rich repeat kinase (LRRK) family) | 2012 | Journal of medicinal chemistry, Jun-14, Volume: 55, Issue:11
| Discovery of selective LRRK2 inhibitors guided by computational analysis and molecular modeling. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] |